Ontology highlight
ABSTRACT:
SUBMITTER: Rosinol L
PROVIDER: S-EPMC6888142 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
Rosiñol Laura L Oriol Albert A Rios Rafael R Sureda Anna A Blanchard María Jesús MJ Hernández Miguel Teodoro MT Martínez-Martínez Rafael R Moraleda Jose M JM Jarque Isidro I Bargay Juan J Gironella Mercedes M de Arriba Felipe F Palomera Luis L González-Montes Yolanda Y Martí Josep M JM Krsnik Isabel I Arguiñano Jose M JM González Maria Esther ME González Ana Pilar AP Casado Luis Felipe LF López-Anglada Lucia L Paiva Bruno B Mateos Maria-Victoria MV San Miguel Jesus F JF Lahuerta Juan-José JJ Bladé Joan J
Blood 20191001 16
Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients aged ≤65 years with NDMM, is evaluating bortezomib (subcutaneous) + lenalidomide + dexamethasone (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT) conditioned with IV busulfan + melphalan vs melphalan and posttransplant consolidation with 2 cycles of VRD. We present grouped response analysis of in ...[more]